# TRUTAKNA (atacicept-vymj)

Type: drug

Source: GetYourBrief — https://getyourbrief.com/entity/trutakna-atacicept-vymj
Canonical HTML page: https://getyourbrief.com/entity/trutakna-atacicept-vymj

## Recent coverage (2 stories, network-wide)

### 42% Proteinuria Cut: FDA Backs Vera’s IgAN Drug with Accelerated Approval
2026-07-12 07:12:03 · Sector: health · Sentiment: Positive · Impact: 8/10 · Sources: 2

The FDA’s accelerated approval of TRUTAKNA marks the first BAFF/APRIL inhibitor for IgA nephropathy, showing a 42% UPCR reduction over placebo. Healthcare providers now have a therapy targeting upstream disease drivers, with launch imminent and a confirmatory trial ongoing.
Full story: https://gethealthbrief.com/story/trutakna-accelerated-approval-iga-nephropathy-health

### Vera’s TRUTAKNA Gets FDA Nod with 42% UPCR Reduction, Awaits Kidney Data
2026-07-12 07:11:54 · Sector: bio · Sentiment: Positive · Impact: 8/10 · Sources: 2

Vera Therapeutics scores an accelerated approval for TRUTAKNA in IgA nephropathy, touting a 42% UPCR reduction vs placebo in Phase 3 ORIGIN 3. The dual BAFF/APRIL inhibitor enters a competitive market with a surrogate endpoint—investors await the confirmatory eGFR data.
Full story: https://getbiobrief.com/story/vera-trutakna-fda-accelerated-approval-iga-nephropathy

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.